Accelerating Global Health Progress
Continuing on from the last World Health Assembly’s event to mark its 50th anniversary, the IFPMA convenes public health experts to discuss the future of global health.
Read More
Handling of Post-Approval Changes to Marketing Authorizations
The brochure describes the complexity of PACs, focusing on the lack of global harmonization, and the impact that has on access. Six case studies are presented, along with recommendations on how the consistent and predictable management of PACs can be beneficial.
Read More
50 Years of Global Health Progress Report
This report traces global health progress over the past 50 years. It reviews some of the research-based biopharmaceutical industry’s major scientific advances, as well as acknowledging challenges the industry faces and areas of unfinished business.
Read more
AMR Industry Alliance
Together with 100+ companies and trade associations from the AMR Industry Alliance, IFPMA is committed to stop superbugs. Check out our first Progress Report!
Read More
IFPMA Corporate Brochure - Committed to a Healthier Future
We hope you find this brochure informative to gain better understanding of the contributions of our industry. We are passionate about the role we play in finding effective and sustainable solutions to today’s most pressing health concerns and look forward to continuing the dialogue with our partners
Read More
IFPMA HEALTH PARTNERSHIPS DIRECTORY
IFPMA hosts the Health Partnerships Directory, a continuously expanding online database that allows users to view, in depth, health partnerships from across the world that involve the research-based biopharmaceutical industry.
Read More
New IFPMA Code of Practice 2019
New IFPMA Code of Practice will enter into force on 1st January 2019
New CodeIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Building trust
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
IFPMA Code of Practice 2019 - Our Ethos
Read More
IFPMA & IFPW Supply chain session 2016 Global Health Forum - long version
The session that took place at 2016 GHF ‘Shaping a sound supply chain ecosystem’ gathered speakers from BMS, IFPW Walgreens Boots Alliance, ICRC and WHO. Moderated by Scrip’s Sukaina Virji. To find out more about the complexities of the pharmaceutical supply chain, to hear what experts think are the essential...
Read More
IFPMA Welcomes Set-Up of New African Medicines Agency
Geneva, 25 May 2018 – To mark Africa Day, soon after African health ministers of 55-country African Union, all gathered at the 71st World Health Assembly, unanimously adopted a treaty to establish the African Medicines Agency, IFPMA seizes this momentum to welcome this important milestone. The new African Medicines Agency...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
ABPI, EFPIA, and IFPMA issue joint statement on AMR
ABPI, EFPIA and IFPMA issue joint statement following publication of the final report by the Review on AMR The Association of the British Pharmaceutical Industry (ABPI), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) have today issued a joint...
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
Cultivating Trust in Healthcare System
This oped was first published in The Pharma Letter on 6 December 2018. Business performance is mostly about the tangible: robust pipeline, successful launches, development of sales, financial results, profit margins, and the like. One less tangible but absolutely crucial measure of success relates to “how” we go about our business. Ethics and building trust matter just as much as the number of medicines that...
Read More
By 2050, superbugs may cost the economy $100 trillion
This oped was first published in the Antimicrobial Resistance campaign in the Guardian on 12 November 2018 Antimicrobial resistance (AMR) is on course to overtake cancer and account for 10m deaths a year by 2050. Already, 700,000 people die from drug-resistant infections (“superbugs”) each year. AMR could cost the global economy up $100 trillion – and push 28m more people into poverty. The life-science...
Read More
La réponse au virus Ebola, enjeu de sécurité sanitaire mondiale
This oped was first published on AGEGI on 25 October 2018. Résumé : Avec Ebola chaque pays est vulnérable face aux épidémies et la solution passe par une couverture universelle de santé et un travail collectif Même si l’Organisation Mondiale de la Santé (OMS) a récemment décidé qu’il n’y a pas lieu de déclarer une épidémie du virus Ebola en République démocratique u Congo (RDC), les...
Read MoreLatest Tweets
@IFPMA @IFPMA 
@IFPMA @IFPMA @IFPMA 